Aurobindo’s Unit 1 clears USFDA audit with zero observations
Smart Money Financial Services :-
Aurobindo’s Unit 1 has cleared USFDA inspection with zero observations. Unit 1 is an API unit with manufacturing capabilities in CVS, CNS, anti-allergics and non-sterile Cephalosporins. The audit started on April 16 and ended on April 20, 2018.
Aurobindo Pharma Ltd is currently trading at Rs637.40 up by Rs18.9 or 3.06% from its previous closing of Rs618.50 on the BSE.
Aurobindo Pharma Ltd is currently trading at Rs637.40 up by Rs18.9 or 3.06% from its previous closing of Rs618.50 on the BSE.
Comments
Post a Comment